Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis (Sep, 10.1007/s10067-020-05305-y, 2020)

Burmester Gerd; Drescher Edit; Hrycaj Pawel; Chien David; Pan Zhiying; Cohen Stanley

首页> 外文期刊>Clinical rheumatology >Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis (Sep, 10.1007/s10067-020-05305-y, 2020)

【24h】

Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis (Sep, 10.1007/s10067-020-05305-y, 2020)

机译：随机双盲研究的功效和安全结果将所提出的生物杀菌ABP 798与中等至重度类风湿性关节炎的受试者中的Rituximab参考产物进行比较（Sep，10.1007 / S10067-020-05305-Y，2020）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical rheumatology》 |2020年第11期|共1页
作者
Burmester Gerd; Drescher Edit; Hrycaj Pawel; Chien David; Pan Zhiying; Cohen Stanley;
展开▼
作者单位

Free Univ Dept Rheumatol &

Clin Immunol Charitepl 1 D-10117 Berlin Germany;

Veszprem Csolnoky Ferenc Cty Hosp Veszprem Hungary;

Koscian Municipal Hosp Rheumatol Koscian Poland;

Amgen Inc Thousand Oaks CA 91320 USA;

Amgen Inc Thousand Oaks CA 91320 USA;

Metroplex Clin Res Ctr Dallas TX USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内科学;
关键词

相似文献

外文文献
中文文献

1. Phase 1 studies comparing safety,tolerability,pharmacokinetics and pharmacodynamics of HLX01(a rituximab biosimilar)to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma [J] . Yuankai Shi, Jifeng Feng, Xiaonan Hong, 中国癌症研究（英文版） . 2021,第003期
2. Efficacy and Safety of Niaoduqing Particles for Delaying Moderate-to-severe Renal Dysfunction: A Randomized,Double-blind, Placebo-controlled, Multicenter Clinical Study [J] . Ying Zheng, Zhao-Hui Ni, Jing-Ai Fang, 中华医学杂志（英文版） . 2017,第020期
3. Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis [J] . Gerd Burmester, Edit Drescher, Pawel Hrycaj, Clinical rheumatology . 2020,第11期

机译：随机双盲研究的功效和安全结果将所提出的生物杀虫剂ABP 798与中等至重度类风湿性关节炎的受试者中的Rituximab参考产物进行比较
4. A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera (R)) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL) [J] . BioDrugs: Clinical immunotherapeutics, biopharmaceuticals, and gene therapy . 2020,第2期

机译：与先前未处理的CD20阳性，低肿瘤负荷滤泡淋巴瘤（LTB-）（LTB-）（LTB-）（LTB-）（LTB-）（LTB - FL）
5. A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera (R)) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL) [J] . Sharman Jeff, Liberati Anna Marina, Silva Rodrigo Santucci, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：与先前未处理的CD20阳性，低肿瘤负荷滤泡淋巴瘤（LTB-FL）的受试者中受试者中受试者中的Rituximab参考产物（Mabthera（R））相比，对PF-05280586（潜在的Rituximab BioSimilar）的随机，双盲疗效和安全性研究
6. Original article: Efficacy safety and immunogenicity of GP2015 an etanercept biosimilar compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III randomised double-blind EQUIRA study [O] . Marco Matucci-Cerinic, Yannick Allanore, Arthur Kavanaugh, 2018

机译：原始文章：依那西普生物仿制药GP2015与参考依那西普在中至重度类风湿性关节炎患者中的功效安全性和免疫原性：比较III期随机双盲EQUIRA研究的24周结果
7. Correction to: Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis [O] . Gerd Burmester, Edit Drescher, Pawel Hrycaj, 2020

机译：校正：随机双盲研究的功效和安全结果将所提出的生物杀虫剂ABP 798与中等至重度类风湿性关节炎的受试者中的Rituximab参考产物进行比较

Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis (Sep, 10.1007/s10067-020-05305-y, 2020)

著录项

相似文献

相关主题

期刊订阅